Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. Academic Article uri icon



  • BACKGROUND: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits, low pill burden, once-daily dosage, and safety. METHODS: Subjects with virologic suppression after > or = 48 weeks of initial antiretroviral therapy with 2 NRTIs and a protease inhibitor (PI) were enrolled. Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks. The primary end point was time to virologic failure (confirmed HIV-1 RNA level > or = 200 copies/mL). Drug resistance at virologic failure was evaluated by standard genotyping and single-genome sequencing (SGS). Residual viremia (1.1-49 copies/mL) was measured by single-copy assay. RESULTS: Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virologic failure by 48 weeks after simplification. Residual viremia did not change significantly after NRTI discontinuation among those without virologic failure but did increase 4-12 weeks before confirmed virologic failure. No major PI-resistance mutations were identified at virologic failure by standard genotyping or SGS. CONCLUSIONS: In this pilot study, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subjects through 48 weeks. PI resistance was not detected among subjects experiencing virologic failure. Larger, randomized trials are warranted to further define the efficacy and safety of this strategy.


  • Wilkin, Timothy
  • McKinnon, John E
  • DiRienzo, A Gregory
  • Mollan, Katie
  • Fletcher, Courtney V
  • Margolis, David M
  • Bastow, Barbara
  • Thal, Gary
  • Woodward, William
  • Godfrey, Catherine
  • Wiegand, Ann
  • Maldarelli, Frank
  • Palmer, Sarah
  • Coffin, John M
  • Mellors, John W
  • Swindells, Susan

publication date

  • March 15, 2009



  • Anti-HIV Agents
  • HIV Infections
  • Oligopeptides
  • Pyridines
  • Ritonavir


PubMed Central ID

  • PMC2680942

Scopus Document Identifier

  • 65649151755

Digital Object Identifier (DOI)

  • 10.1086/597119

PubMed ID

  • 19191590

Additional Document Info


  • 199


  • 6